Lung cancer is one of the most challenging and costly medical conditions to treat, yet India has emerged as a leading destination for affordable, world-class care. The lung cancer treatment cost in India typically ranges from ₹1.3 lakh for early-stage surgery to over ₹20 lakh for advanced-stage treatment involving immunotherapy or targeted therapy. It 60–80% more affordable than equivalent care in the US or UK. The total cost depends on several factors, including the stage of cancer at diagnosis, the type of treatment required (surgery, chemotherapy, radiation, targeted therapy, or immunotherapy), the hospital tier, and the city of treatment.
Leading cancer centers such as Tata Memorial Hospital in Mumbai, AIIMS Delhi, Apollo, Fortis, and Medanta offer internationally benchmarked oncology protocols at a fraction of Western prices. Government schemes like Ayushman Bharat PM-JAY further reduce the financial burden for eligible patients, covering up to ₹5 lakh per year at empaneled hospitals.
This complete 2025 guide breaks down every cost component from diagnostics to drug therapy, so patients and families can plan with clarity and confidence.
Why India for Lung Cancer Treatment?
Lung cancer is the leading cause of cancer-related death in India. According to data from the Indian Council of Medical Research (ICMR), the country is projected to record over 81,000 new lung cancer cases in 2025. A figure that has nearly doubled over the past decade, driven by rising tobacco use, worsening urban air pollution, and occupational chemical exposures.
Despite this burden, India has emerged as one of the most sought-after destinations for lung cancer treatment for both domestic patients and international medical tourists. The reasons are compelling: world-class oncology centres, internationally trained thoracic surgeons, access to the latest drug protocols, and treatment costs that are 60–80% lower than equivalent care in the United States or United Kingdom.
Key Fact: The average total cost of lung cancer treatment in India ranges from ₹1.3 lakh for early-stage surgery to ₹15–20 lakh or more for advanced-stage multi-modality treatment involving immunotherapy or targeted drugs. Understanding what drives this range is the most useful thing a patient or family can do before their first oncology appointment.
Types of Lung Cancer and Their Impact on Cost
Not all lung cancers are treated or priced the same. The biology of the tumour determines which treatments are possible, and that directly shapes what the final bill will look like.
Non-Small Cell Lung Cancer (NSCLC)
NSCLC accounts for roughly 80–85% of all lung cancer diagnoses. It includes adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. Because NSCLC often responds to targeted therapy (especially when EGFR, ALK, or ROS1 mutations are present), biomarker testing is a critical early step that can both improve outcomes and change the cost trajectory significantly.
Small Cell Lung Cancer (SCLC)
SCLC is less common but more aggressive. It spreads quickly and is usually diagnosed at an advanced stage. Surgery is rarely indicated; the standard protocol involves platinum-based chemotherapy combined with radiation, and increasingly, immunotherapy maintenance. Treatment tends to be intensive and ongoing, making total costs harder to predict upfront.
Clinical Insight: For NSCLC patients, identifying a driver mutation early (EGFR, ALK, ROS1, KRAS) can shift treatment from generic chemotherapy to a targeted oral drug, sometimes reducing hospitalisation costs while improving survival outcomes. Biomarker testing costs approximately ₹15,000–₹40,000 and is almost always worth doing.
Detailed Cost by Treatment Type
- Surgery
Surgery remains the most effective treatment for early-stage localised lung cancer. The surgical approach used — open thoracotomy, minimally invasive VATS, or robotic-assisted — significantly affects both the hospital bill and the recovery timeline.
| Surgical Procedure | Description | Cost Range (INR) |
| Wedge Resection | Removal of a small, wedge-shaped section of the lung | ₹2,00,000 – ₹3,50,000 |
| Segmentectomy | Removal of a lung segment; used for smaller tumours | ₹2,50,000 – ₹4,50,000 |
| Lobectomy (Open) | Removal of an entire lung lobe; most common surgical treatment | ₹3,00,000 – ₹8,00,000 |
| VATS Lobectomy | Minimally invasive keyhole approach; faster recovery | ₹4,00,000 – ₹7,00,000 |
| Robotic Surgery | Robot-assisted precision surgery; highest precision, higher cost | ₹8,00,000 – ₹12,50,000 |
| Pneumonectomy | Removal of an entire lung; for extensive disease | ₹4,00,000 – ₹10,00,000 |
Important Note on Surgery Costs: The figures above represent surgeon + OT + anaesthesia + a standard hospital stay. They typically exclude pre-surgical diagnostics (₹67,000–₹90,000), post-operative ICU admission if required, and follow-up consultations. Always ask for an all-inclusive package quote in writing before proceeding.
- Chemotherapy
Chemotherapy uses cytotoxic drugs, administered intravenously or orally, to kill rapidly dividing cancer cells. It is used as primary treatment for SCLC, as adjuvant therapy after surgery, and combined with radiation for locally advanced disease. Most patients require 4–6 cycles, with each cycle administered 3 weeks apart.
| Chemotherapy Type | Cost Per Cycle | Typical Cycles | Total Estimated Cost |
| Standard Platinum-based (e.g., Carboplatin + Paclitaxel) | ₹50,000 – ₹80,000 | 4–6 | ₹2,00,000 – ₹4,80,000 |
| Pemetrexed-based (for adenocarcinoma) | ₹80,000 – ₹1,50,000 | 4–6 | ₹3,20,000 – ₹9,00,000 |
| Concurrent Chemoradiation (Stage III) | ₹70,000 – ₹1,20,000 | 5–6 | ₹3,50,000 – ₹7,20,000 |
- Radiation Therapy
Radiation therapy uses high-energy X-rays or proton beams to destroy cancer cells. It may be delivered as the primary treatment (when surgery isn’t feasible), after surgery to eliminate residual cancer cells, or palliatively to relieve symptoms such as bone pain or breathing difficulty.
| Radiation Modality | Cost Range (Full Course) | Notes |
| Conventional EBRT (3D-CRT) | ₹1,00,000 – ₹2,50,000 | 25–35 sessions over 5–7 weeks |
| IMRT / IGRT | ₹2,50,000 – ₹4,50,000 | Precision targeting; spares healthy tissue better |
| SBRT / SABR | ₹3,00,000 – ₹5,50,000 | 5 high-dose fractions; preferred for early-stage inoperable patients |
| Proton Beam Therapy | ₹10,00,000 – ₹20,00,000 | Available at select centres; reduces radiation to surrounding organs |
- Targeted Therapy
Targeted therapy is an oral medication that blocks specific genetic mutations driving tumour growth. For patients with actionable mutations (EGFR, ALK, ROS1, BRAF), it is typically the most effective first-line treatment and avoids the side effects of traditional chemotherapy. The cost varies enormously by drug and whether a generic equivalent is available.
| Drug (Mutation Target) | Brand Cost / Month | Generic Cost / Month |
| Gefitinib — Iressa (EGFR) | ₹35,000 – ₹45,000 | ₹8,000 – ₹15,000 |
| Erlotinib — Tarceva (EGFR) | ₹40,000 – ₹55,000 | ₹10,000 – ₹18,000 |
| Osimertinib — Tagrisso (EGFR T790M) | ₹1,80,000 – ₹2,20,000 | ₹60,000 – ₹90,000 (generic Osimertinib) |
| Crizotinib — Xalkori (ALK/ROS1) | ₹1,50,000 – ₹2,00,000 | ₹40,000 – ₹70,000 |
| Alectinib — Alecensaro (ALK) | ₹1,60,000 – ₹2,20,000 | ₹50,000 – ₹80,000 |
- Immunotherapy
Immunotherapy uses checkpoint inhibitor drugs (PD-1/PD-L1 inhibitors) to help the patient’s own immune system recognise and destroy cancer cells. It has transformed outcomes for metastatic NSCLC and is increasingly used in Stage III disease. Drugs like Pembrolizumab (Keytruda) and Nivolumab (Opdivo) are now CDSCO/DCGI-approved in India.
| Drug | Cost Per Cycle / Dose | Typical Frequency |
| Pembrolizumab (Keytruda) | ₹2,00,000 – ₹3,00,000 | Every 3 weeks |
| Nivolumab (Opdivo) | ₹1,50,000 – ₹2,50,000 | Every 2–4 weeks |
| Atezolizumab (Tecentriq) | ₹1,80,000 – ₹2,80,000 | Every 3–4 weeks |
| Durvalumab (Imfinzi — maintenance) | ₹1,50,000 – ₹2,20,000 | Every 4 weeks for up to 12 months |
Cost-Saving Tip: Ask your oncologist whether biosimilar or generic versions of immunotherapy drugs are available. For some agents, the cost differential can be 30–50% lower than the originator brand, with no clinically meaningful difference in outcomes for approved indications.
Cost by Cancer Stage
Stage at diagnosis is the single biggest driver of total treatment cost. The earlier the stage, the lower the total bill — and the better the long-term outcome.
Stage I – ₹1.3L – ₹6L
Stage II – ₹2.5L – ₹8L
Stage III – ₹5L – ₹12L
Stage IV – ₹8L – ₹20L+
Stage I & II (Localised): Surgery — ideally minimally invasive VATS — is the primary treatment. Some patients may require short-course adjuvant chemotherapy or radiation. Total costs in the ₹2.5 lakh – ₹6 lakh range are typical.
Stage III (Locally Advanced): Treatment usually involves concurrent chemoradiation, sometimes followed by immunotherapy maintenance (e.g., Durvalumab for 12 months after chemoradiation). Costs climb to ₹5 lakh – ₹12 lakh depending on the number of cycles and duration.
Stage IV (Metastatic): This is where costs are hardest to predict upfront. Targeted therapy (if a driver mutation is present) or immunotherapy becomes the backbone of treatment. Monthly drug costs alone can be substantial, and treatment is ongoing rather than time-limited. Total annual costs in the ₹10 lakh – ₹20 lakh+ range are realistic for patients on premium biologics.
Diagnostic Costs You Must Account For
Before any treatment can begin, a series of diagnostic tests are required to confirm the diagnosis, stage the cancer, and assess the patient’s fitness for treatment. These costs are often overlooked in initial estimates but can add ₹67,000–₹90,000 to the overall bill.
| Diagnostic Test | Purpose | Cost Range (INR) |
| Low-Dose CT Scan (LDCT) | Screening / initial detection | ₹3,000 – ₹8,000 |
| Contrast-Enhanced CT (CECT Chest) | Tumour characterisation and staging | ₹4,000 – ₹10,000 |
| PET-CT Scan | Whole-body staging; detect spread | ₹23,000 – ₹30,000 |
| CT-Guided Biopsy | Tissue diagnosis — confirms cancer type | ₹10,000 – ₹25,000 |
| Bronchoscopy + EBUS | Biopsy of central tumours / lymph nodes | ₹15,000 – ₹35,000 |
| Molecular / Biomarker Testing (NGS) | EGFR, ALK, ROS1, KRAS, PDL-1 testing | ₹15,000 – ₹45,000 |
| Pulmonary Function Tests (PFT) | Fitness for surgery assessment | ₹2,000 – ₹5,000 |
| MRI Brain | Check for brain metastases (Stage III/IV) | ₹5,000 – ₹12,000 |
Cost by City
Geography matters. Tier-1 metros — Mumbai, Delhi, Bengaluru — have higher overhead costs reflected in hospital pricing, while Tier-2 cities can offer the same clinical quality at a 20–30% discount. Government hospitals like AIIMS Delhi and Tata Memorial Mumbai offer subsidised world-class care but come with longer wait times.
| City | Surgery (Lobectomy) | Chemotherapy (Per Cycle) | Overall Treatment Range |
| Mumbai | ₹4L – ₹9L | ₹60K – ₹1.5L | ₹5L – ₹20L |
| Delhi / NCR | ₹3L – ₹8L | ₹50K – ₹1.2L | ₹4L – ₹18L |
| Bengaluru | ₹3.5L – ₹8L | ₹55K – ₹1.3L | ₹4L – ₹18L |
| Chennai | ₹3L – ₹7L | ₹50K – ₹1.2L | ₹3.5L – ₹16L |
| Hyderabad | ₹2.5L – ₹6L | ₹45K – ₹1.1L | ₹3L – ₹15L |
| Kolkata | ₹2.5L – ₹5.5L | ₹40K – ₹1L | ₹3L – ₹14L |
| Pune | ₹2.5L – ₹6L | ₹45K – ₹1.1L | ₹3L – ₹15L |
| AIIMS Delhi (Govt.) | ₹1L – ₹4L | ₹15K – ₹50K | ₹1.3L – ₹8L |
Key Factors That Affect the Final Bill
Stage at Diagnosis — The most impactful variable. Stage I treatment may cost ₹2–5 lakh; Stage IV treatment can exceed ₹20 lakh per year. Early detection via LDCT screening (₹3,000–₹8,000) is the highest-ROI intervention available.
Treatment Modality — Surgery, chemotherapy, radiation, targeted therapy, and immunotherapy each carry very different price points. Multi-modality treatment for advanced disease stacks all of these, multiplying cost.
Hospital Type & Tier — Private Tier-1 hospitals cost 3–5x more than government teaching hospitals for identical procedures. Tata Memorial (Mumbai) and AIIMS (Delhi) offer subsidised world-class care with longer wait times.
Room Category — General ward vs. private room can add ₹5,000–₹30,000 per day to the hospitalisation cost, which accumulates quickly over a 5–10 day surgical stay.
Biomarker Status — Identifying a targetable mutation (EGFR, ALK) can shift treatment from expensive IV chemotherapy to an oral pill at home, potentially lowering hospitalisation costs even if monthly drug costs are higher.
Branded vs. Generic Drugs — Generic alternatives to many targeted therapy and immunotherapy agents are legally available in India at 30–60% lower prices. Ask your oncologist explicitly.
Number of Treatment Cycles / Duration — Chemo and immunotherapy are administered over months. A longer treatment course directly proportional increases the total cost.
Complications & Comorbidities — Post-surgical complications, infections, or pre-existing conditions (COPD, diabetes) that complicate treatment can significantly extend hospital stays and add unpredictable costs.
Top Hospitals for Lung Cancer Treatment in India
Tata Memorial Hospital – Mumbai · Government (Subsidised)
India’s premier dedicated cancer center. World-class thoracic oncology, high volume, subsidised costs for patients with financial need.
AIIMS Delhi – New Delhi · Government (Subsidised)
Leading public tertiary centre. Full range of lung cancer surgery and treatment at government rates. Significant wait times for elective procedures.
Apollo Hospitals – Pan-India · Private
Largest private chain for oncology. VATS and robotic thoracic surgery available at multiple campuses. Strong international patient programmes.
Fortis Memorial Research Institute – Gurugram · Private
Advanced robotic surgery, da Vinci platform. Multidisciplinary tumour board. Strong for complex resections and Stage III management.
Medanta — The Medicity – Gurugram · Private
Dedicated thoracic surgery division. On-site PET-CT, linear accelerator radiation. Comprehensive under one roof.
Max Super Speciality Hospital – Delhi NCR · Private
Nanavati Max (Mumbai) has a dedicated thoracic surgery programme. Transparent package pricing available on request.
Rajiv Gandhi Cancer Institute – New Delhi · Private
Dedicated cancer hospital with focus on thoracic oncology. PET-CT imaging, robotic surgery, and clinical trials available.
Manipal Comprehensive Cancer Care – Bengaluru / Pan-India
Regional cancer centres with strong radiation oncology. Cost-effective compared to Delhi and Mumbai for similar quality.
India vs. Other Countries: A Cost Comparison
For international medical tourists, India’s cost advantage is significant. The quality of care at top-tier Indian cancer hospitals — in terms of surgical outcomes, drug access, and multidisciplinary protocols — is comparable to leading Western centers.
| Treatment | India | USA | UK | Singapore |
| Lobectomy (Surgery) | $3,500 – $10,000 | $50,000 – $100,000 | $20,000 – $40,000 | $18,000 – $35,000 |
| Chemotherapy (per cycle) | $600 – $1,800 | $8,000 – $20,000 | $3,000 – $7,000 | $2,500 – $6,000 |
| Immunotherapy (per cycle) | $1,800 – $5,000 | $20,000 – $40,000 | $10,000 – $20,000 | $8,000 – $16,000 |
| Full Treatment (Stage I) | $4,000 – $8,000 | $60,000 – $150,000 | $25,000 – $50,000 | $20,000 – $45,000 |
Insurance, Government Schemes & Financial Assistance
The high cost of lung cancer treatment does not have to fall entirely on the patient. Several public and private mechanisms exist to reduce the financial burden.
Government Health Schemes
| Scheme | Coverage | Who Qualifies |
| Ayushman Bharat PM-JAY | Up to ₹5 lakh per year | Economically weaker sections as per SECC database |
| CGHS (Central Govt. Health Scheme) | Comprehensive; covers most treatments | Central government employees & pensioners |
| ECHS (Ex-Servicemen) | Comprehensive coverage | Ex-servicemen and their families |
| State CM Relief Funds | Varies by state; ₹1–5 lakh typical | BPL and economically distressed patients |
Private Health Insurance
Most comprehensive health insurance policies in India cover surgery, chemotherapy, and radiation for cancer. However, advanced biologics — targeted therapy and immunotherapy — may require additional riders or pre-authorisation. Key points to check on your policy:
- Is there a cancer-specific rider or critical illness benefit?
- Does the policy cover immunotherapy and targeted oral drugs?
- Is there a day-care treatment clause covering outpatient chemotherapy?
- What is the sub-limit on room rent (affects all other charges)?
- Is there a co-pay clause that activates after a certain age?
Pharmaceutical Patient Assistance Programmes
Several pharma manufacturers — including AstraZeneca (Tagrisso), MSD (Keytruda), and BMS (Opdivo) — operate patient assistance programmes in India that provide drugs at significantly reduced cost or free of charge for eligible patients who cannot afford commercial pricing. Ask your oncologist or the hospital’s medical social worker for referrals.
Practical Tip: Many leading hospitals have a dedicated oncology financial counsellor or social worker. Before beginning treatment, schedule a session with them. They can identify every applicable scheme, drug access programme, and instalment payment plan available for your specific situation — a step most families skip and later regret.
Frequently Asked Questions
What is the minimum cost to treat lung cancer in India?
For a Stage I patient undergoing minimally invasive VATS surgery at a government hospital like AIIMS or Tata Memorial, total costs including diagnostics can be as low as ₹1.3 lakh – ₹3 lakh. At a private hospital, the same treatment would be ₹4 lakh – ₹8 lakh.
Is lung cancer treatment cheaper in India than in Western countries?
Yes. Lung cancer treatment in India is typically 60–80% less expensive than equivalent care in the USA or UK, with comparable clinical outcomes at top-tier centres. A lobectomy that costs $70,000–$100,000 in the US typically costs $3,500–$10,000 in India.
How many chemotherapy cycles are needed for lung cancer?
Most protocols recommend 4–6 cycles of first-line chemotherapy, administered every 3 weeks. For maintenance therapy, this may continue for longer. The exact number depends on response to treatment, the patient’s tolerance, and the oncologist’s assessment.
Does Ayushman Bharat PM-JAY cover lung cancer treatment?
Yes. PM-JAY covers lung cancer treatment — including surgery, chemotherapy, and radiation — up to ₹5 lakh per year at empanelled hospitals. It does not automatically cover all immunotherapy drugs, so check with the empanelled hospital’s billing department for specific drug coverage.
What is the survival rate for lung cancer treated in India?
Five-year survival rates vary significantly by stage. Stage I NSCLC treated with surgery has a 5-year survival rate of 60–80%. Stage IV disease has a much lower 5-year rate (under 10% historically), though immunotherapy and targeted therapy have meaningfully improved median survival for patients with actionable mutations or high PD-L1 expression.
Is immunotherapy available in India for lung cancer?
Yes. CDSCO/DCGI-approved immunotherapy agents including Pembrolizumab (Keytruda), Nivolumab (Opdivo), Atezolizumab (Tecentriq), and Durvalumab (Imfinzi) are available at major cancer centres across India. Cost ranges from ₹1.5 lakh to ₹3 lakh per cycle depending on the drug and dose.
How do I get a package quote from an Indian hospital?
Contact the hospital’s International Patient Services or Medical Services Coordination team directly. Reputable hospitals will provide a detailed written cost estimate covering surgery, anaesthesia, ICU, ward stay, and the first follow-up. Always request line-item transparency and ask specifically about what is excluded from the package price.
Medical & Financial Disclaimer: All cost figures in this guide are approximate estimates compiled from publicly available data across leading Indian hospitals and medical tourism platforms as of mid-2025. Actual costs will vary based on your specific diagnosis, treating institution, doctor, treatment response, and insurance coverage. This content is for informational purposes only and does not constitute medical or financial advice. Always consult a qualified oncologist for a treatment plan and the hospital’s billing department for an individualized cost estimate.
